Trovagene (NASDAQ:TROV) initiates a Phase 2 clinical trial, UNITE, assessing the combination of PCM-075 and Johnson & Johnson's ZYTIGA (abiraterone acetate) in patients with metastatic castration-resistant prostate cancer (mCRPC).
UNITE will enroll 25 mCRPC patients who are showing early signs of progression while being treated with ZYTIGA. The primary endpoint will be the proportion of subjects achieving disease control at week 12 as defined by the lack of progression of the prostate cancer biomarker PSA (prostate-specific antigen).
PCM-075 inhibits an enzyme called serine/threonine polo-like-kinase 1 (PLK 1) which is overexpressed in a range of blood cancers and solid tumors. Studies have shown that inhibiting polo-like-kinases can lead to cancer cell death.
Subscribe for full text news in your inbox